Mergers & Acquisitions ·
Supernus terminates UBS credit line ahead of planned merger with Indivior Pharmaceuticals
SUPNSupernus, Inc.
On October 20, 2026, Supernus Pharmaceuticals terminated its uncommitted demand revolving credit facility with UBS Bank USA. The termination was executed in anticipation of the company's previously announced business combination with Indivior Pharmaceuticals pursuant to an Agreement and Plan of Merger dated August 1, 2026. As of the termination date, no advances or obligations were outstanding under the facility, and no early termination penalties were incurred. The bank’s security interests in the collateral were released upon termination. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for neurological disorders.